Company profile
Shandong New Time Pharmaceutical Co., Ltd.
Privately held: no public share price (Chinese API/formulation manufacturer, one of several subsidiaries of the privately-held Lunan Pharmaceutical Group; no independent public listing found (made-in-china.com, D&B, lunanpharma.com). Sources: https://clinicaltrials.gov/study/NCT04984434 Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | BCMA x CD3Multispecific antibody | Multiple Myeloma |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.